Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation

S. Blondel, A. L. Egesipe, P. Picardi, A. L. Jaskowiak, M. Notarnicola, J. Ragot, J. Tournois, A. Le Corf, B. Brinon, P. Poydenot, P. Georges, C. Navarro, P. R. Pitrez, L. Ferreira, G. Bollot, C. Bauvais, D. Laustriat, A. Mejat, A. De Sandre-Giovannoli, N. LevyM. Bifulco, M. Peschanski, X. Nissan

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by a dramatic appearance of premature aging. HGPS is due to a single-base substitution in exon 11 of the LMNA gene (c.1824C>T) leading to the production of a toxic form of the prelamin A protein called progerin. Because farnesylation process had been shown to control progerin toxicity, in this study we have developed a screening method permitting to identify new pharmacological inhibitors of farnesylation. For this, we have used the unique potential of pluripotent stem cells to have access to an unlimited and relevant biological resource and test 21 608 small molecules. This study identified several compounds, called monoaminopyrimidines, which target two key enzymes of the farnesylation process, farnesyl pyrophosphate synthase and farnesyl transferase, and rescue in vitro phenotypes associated with HGPS. Our results opens up new therapeutic possibilities for the treatment of HGPS by identifying a new family of protein farnesylation inhibitors, and which may also be applicable to cancers and diseases associated with mutations that involve farnesylated proteins.

Original languageEnglish
Article numbere2105
JournalCell Death and Disease
Volume7
Issue number2
DOIs
Publication statusPublished - 2016

Fingerprint

Progeria
Prenylation
Pluripotent Stem Cells
Preclinical Drug Evaluations
Protein Prenylation
Premature Aging
Inborn Genetic Diseases
Poisons
Transferases
Exons
Proteins
Pharmacology
Phenotype
Mutation
2-aminopyrimidine
Enzymes
Genes
Neoplasms

ASJC Scopus subject areas

  • Cell Biology
  • Immunology
  • Cancer Research
  • Cellular and Molecular Neuroscience

Cite this

Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. / Blondel, S.; Egesipe, A. L.; Picardi, P.; Jaskowiak, A. L.; Notarnicola, M.; Ragot, J.; Tournois, J.; Le Corf, A.; Brinon, B.; Poydenot, P.; Georges, P.; Navarro, C.; Pitrez, P. R.; Ferreira, L.; Bollot, G.; Bauvais, C.; Laustriat, D.; Mejat, A.; De Sandre-Giovannoli, A.; Levy, N.; Bifulco, M.; Peschanski, M.; Nissan, X.

In: Cell Death and Disease, Vol. 7, No. 2, e2105, 2016.

Research output: Contribution to journalArticle

Blondel, S, Egesipe, AL, Picardi, P, Jaskowiak, AL, Notarnicola, M, Ragot, J, Tournois, J, Le Corf, A, Brinon, B, Poydenot, P, Georges, P, Navarro, C, Pitrez, PR, Ferreira, L, Bollot, G, Bauvais, C, Laustriat, D, Mejat, A, De Sandre-Giovannoli, A, Levy, N, Bifulco, M, Peschanski, M & Nissan, X 2016, 'Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation', Cell Death and Disease, vol. 7, no. 2, e2105. https://doi.org/10.1038/cddis.2015.374
Blondel, S. ; Egesipe, A. L. ; Picardi, P. ; Jaskowiak, A. L. ; Notarnicola, M. ; Ragot, J. ; Tournois, J. ; Le Corf, A. ; Brinon, B. ; Poydenot, P. ; Georges, P. ; Navarro, C. ; Pitrez, P. R. ; Ferreira, L. ; Bollot, G. ; Bauvais, C. ; Laustriat, D. ; Mejat, A. ; De Sandre-Giovannoli, A. ; Levy, N. ; Bifulco, M. ; Peschanski, M. ; Nissan, X. / Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. In: Cell Death and Disease. 2016 ; Vol. 7, No. 2.
@article{b7403cd49ed34d53b72541195fb0b897,
title = "Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation",
abstract = "Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by a dramatic appearance of premature aging. HGPS is due to a single-base substitution in exon 11 of the LMNA gene (c.1824C>T) leading to the production of a toxic form of the prelamin A protein called progerin. Because farnesylation process had been shown to control progerin toxicity, in this study we have developed a screening method permitting to identify new pharmacological inhibitors of farnesylation. For this, we have used the unique potential of pluripotent stem cells to have access to an unlimited and relevant biological resource and test 21 608 small molecules. This study identified several compounds, called monoaminopyrimidines, which target two key enzymes of the farnesylation process, farnesyl pyrophosphate synthase and farnesyl transferase, and rescue in vitro phenotypes associated with HGPS. Our results opens up new therapeutic possibilities for the treatment of HGPS by identifying a new family of protein farnesylation inhibitors, and which may also be applicable to cancers and diseases associated with mutations that involve farnesylated proteins.",
author = "S. Blondel and Egesipe, {A. L.} and P. Picardi and Jaskowiak, {A. L.} and M. Notarnicola and J. Ragot and J. Tournois and {Le Corf}, A. and B. Brinon and P. Poydenot and P. Georges and C. Navarro and Pitrez, {P. R.} and L. Ferreira and G. Bollot and C. Bauvais and D. Laustriat and A. Mejat and {De Sandre-Giovannoli}, A. and N. Levy and M. Bifulco and M. Peschanski and X. Nissan",
year = "2016",
doi = "10.1038/cddis.2015.374",
language = "English",
volume = "7",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation

AU - Blondel, S.

AU - Egesipe, A. L.

AU - Picardi, P.

AU - Jaskowiak, A. L.

AU - Notarnicola, M.

AU - Ragot, J.

AU - Tournois, J.

AU - Le Corf, A.

AU - Brinon, B.

AU - Poydenot, P.

AU - Georges, P.

AU - Navarro, C.

AU - Pitrez, P. R.

AU - Ferreira, L.

AU - Bollot, G.

AU - Bauvais, C.

AU - Laustriat, D.

AU - Mejat, A.

AU - De Sandre-Giovannoli, A.

AU - Levy, N.

AU - Bifulco, M.

AU - Peschanski, M.

AU - Nissan, X.

PY - 2016

Y1 - 2016

N2 - Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by a dramatic appearance of premature aging. HGPS is due to a single-base substitution in exon 11 of the LMNA gene (c.1824C>T) leading to the production of a toxic form of the prelamin A protein called progerin. Because farnesylation process had been shown to control progerin toxicity, in this study we have developed a screening method permitting to identify new pharmacological inhibitors of farnesylation. For this, we have used the unique potential of pluripotent stem cells to have access to an unlimited and relevant biological resource and test 21 608 small molecules. This study identified several compounds, called monoaminopyrimidines, which target two key enzymes of the farnesylation process, farnesyl pyrophosphate synthase and farnesyl transferase, and rescue in vitro phenotypes associated with HGPS. Our results opens up new therapeutic possibilities for the treatment of HGPS by identifying a new family of protein farnesylation inhibitors, and which may also be applicable to cancers and diseases associated with mutations that involve farnesylated proteins.

AB - Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by a dramatic appearance of premature aging. HGPS is due to a single-base substitution in exon 11 of the LMNA gene (c.1824C>T) leading to the production of a toxic form of the prelamin A protein called progerin. Because farnesylation process had been shown to control progerin toxicity, in this study we have developed a screening method permitting to identify new pharmacological inhibitors of farnesylation. For this, we have used the unique potential of pluripotent stem cells to have access to an unlimited and relevant biological resource and test 21 608 small molecules. This study identified several compounds, called monoaminopyrimidines, which target two key enzymes of the farnesylation process, farnesyl pyrophosphate synthase and farnesyl transferase, and rescue in vitro phenotypes associated with HGPS. Our results opens up new therapeutic possibilities for the treatment of HGPS by identifying a new family of protein farnesylation inhibitors, and which may also be applicable to cancers and diseases associated with mutations that involve farnesylated proteins.

UR - http://www.scopus.com/inward/record.url?scp=84986275726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986275726&partnerID=8YFLogxK

U2 - 10.1038/cddis.2015.374

DO - 10.1038/cddis.2015.374

M3 - Article

AN - SCOPUS:84986275726

VL - 7

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 2

M1 - e2105

ER -